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A bs t r ac t
Background

Long-acting beta-agonist (LABA) therapy improves symptoms in patients whose asthma is poorly controlled by an inhaled glucocorticoid alone. Alternative treatments
for adults with uncontrolled asthma are needed.
Methods

In a three-way, double-blind, triple-dummy crossover trial involving 210 patients with
asthma, we evaluated the addition of tiotropium bromide (a long-acting anticholinergic agent approved for the treatment of chronic obstructive pulmonary disease
but not asthma) to an inhaled glucocorticoid, as compared with a doubling of the
dose of the inhaled glucocorticoid (primary superiority comparison) or the addition
of the LABA salmeterol (secondary noninferiority comparison).
Results

The use of tiotropium resulted in a superior primary outcome, as compared with a
doubling of the dose of an inhaled glucocorticoid, as assessed by measuring the
morning peak expiratory flow (PEF), with a mean difference of 25.8 liters per minute (P<0.001) and superiority in most secondary outcomes, including evening PEF,
with a difference of 35.3 liters per minute (P<0.001); the proportion of asthmacontrol days, with a difference of 0.079 (P = 0.01); the forced expiratory volume in
1 second (FEV1) before bronchodilation, with a difference of 0.10 liters (P = 0.004);
and daily symptom scores, with a difference of −0.11 points (P<0.001). The addition
of tiotropium was also noninferior to the addition of salmeterol for all assessed
outcomes and increased the prebronchodilator FEV1 more than did salmeterol, with
a difference of 0.11 liters (P = 0.003).
Conclusions

When added to an inhaled glucocorticoid, tiotropium improved symptoms and lung
function in patients with inadequately controlled asthma. Its effects appeared to be
equivalent to those with the addition of salmeterol. (Funded by the National Heart,
Lung, and Blood Institute; ClinicalTrials.gov number, NCT00565266.)
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any adults with asthma have inadequate control of symptoms when receiving a low-to-medium dose of an inhaled glucocorticoid.1,2 Treatment options include
the addition of a leukotriene modifier,2 the addition of a long-acting beta-agonist (LABA),2-4 or an
increased dose of an inhaled glucocorticoid.2 Current guidelines of the National Asthma Education
and Prevention Program favor the last two options.2 In recent communications, however, the
Food and Drug Administration (FDA)5 and asthma experts6,7 have questioned the safety of LABA
therapy and suggested strategies to minimize the
use of these drugs. Because of such concerns and
the heterogeneity of patients with asthma, alternative controller agents are needed.
Whether anticholinergic agents are useful for
asthma management is not clear. A Cochrane Review reported that there is no justification for
routinely introducing anticholinergic agents (the
report focused on ipratropium bromide), while acknowledging that the role of long-acting anticholinergic agents such as tiotropium bromide has
not been established.8 Tiotropium has a duration
of action of more than 24 hours9,10 and was approved by the FDA for the treatment of chronic
obstructive pulmonary disease (COPD) in January
2004. However, tiotropium has not been approved
for the treatment of asthma.
In a double-blind, three-way, crossover trial,
called the Tiotropium Bromide as an Alternative
to Increased Inhaled Glucocorticoid in Patients
Inadequately Controlled on a Lower Dose of Inhaled Corticosteroid (TALC) study, we tested two
hypotheses. The primary hypothesis stated that in
patients with asthma that is inadequately controlled by an inhaled glucocorticoid alone, the addition of tiotropium bromide would be superior
to a doubling of the dose of an inhaled glucocorticoid. The secondary hypothesis stated that in
such patients, the addition of tiotropium would
not be inferior to the addition of a LABA. We
evaluated the primary outcome, the morning peak
expiratory flow (PEF), as well as additional outcomes, in 210 patients with asthma inadequately controlled by a low dose of an inhaled glucocorticoid.

of
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ies. One of the studies, called the Best Adjustment
Strategy for Asthma over Long Term (BASALT)
trial (ClinicalTrials.gov number, NCT00495157),
involved patients with mild-to-moderate disease,
and the results are not reported here. A total of
342 patients underwent randomization in the
BASALT study, 210 patients underwent randomization in the TALC study (with the last patients
completing the study on May 21, 2010), and 274
patients were excluded from both studies (Fig. 1).
The inclusion criteria for enrollment in the common run-in period for both studies included an
age of at least 18 years, a history of asthma confirmed by bronchodilator reversibility or bronchial hyperresponsiveness, a forced expiratory volume in 1 second (FEV1) of more than 40% of the
predicted value, and nonsmoking status (<10 packyears). Exclusion criteria are listed in the Supplementary Appendix, available with the full text of
this article at NEJM.org.
The study was approved by the committee on
human research at each institution. All patients
provided written informed consent.
Study Protocol

At the onset of the 4-week run-in period, all patients were treated with a hydrofluoroalkane metered-dose inhaler of beclomethasone (Qvar) at a
dose of 80 μg (2 puffs of 40 μg) twice daily (Fig. 2,
and Fig. S1 in the Supplementary Appendix). All
other asthma medications were stopped. Patients
were eligible for assignment to either the TALC
study or the BASALT study if at week 4 they had
at least 75% adherence to the run-in protocol (as
shown by peak flow, diary card, and study medications), an FEV1 of more than 40% of the predicted value, and no need for additional asthma
medications. Patients were assigned to the TALC
study if at week 4 they had no medical contraindication to tiotropium and the FEV1 was 70% or
less of the predicted value or if during the final
2 weeks of the run-in period they had symptoms
6 or more days per week or used a rescue inhaler
6 or more days per week or were awakened by
symptoms of asthma two nights or more per week.
Weeks 3 and 4 of the run-in period provided
baseline data for the first treatment period and
inflammatory biomarkers. Patients were treated
for a 14-week period with the run-in dose of bec
Me thods
lomethasone plus inhaled tiotropium bromide
Study Patients
(Spiriva HandiHaler) at a dose of 18 μg every
Beginning in June 2007, we enrolled 826 patients morning plus a salmeterol placebo inhaler; 160 μg
in a common run-in period for two asthma stud- (2 puffs of 80 μg) twice daily of beclomethasone
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826 Patients were enrolled in common
run-in, starting in June 2007

174 Were excluded during common run-in
54 Withdrew consent
16 Were lost to follow-up
1 Had drug-related adverse event
1 Had adverse event not related to asthma
or drugs
59 Had a compliance issue
9 Had asthma exacerbation
19 Were ineligible
15 Had other reason

652 Were eligible for assignment

363 Were assigned to BASALT,
starting in July 2007

289 Were assigned to TALC,
starting in July 2007

21 Were excluded before BASALT randomization
9 Withdrew consent
1 Was lost to follow-up
7 Had compliance issues
2 Were assigned in error
2 Had other reason

342 Underwent randomization to
BASALT by October 2009

79 Were excluded before TALC randomization
57 Were assigned before TALC start date
22 Were assigned after TALC recruitment
closed

210 Underwent randomization to TALC
by June 2009

23 Dropped out in TALC period 1
5 Dropped out in TALC period 2
8 Dropped out in TALC period 3
0 Dropped out during TALC washout period

7 Dropped out while receiving tiotropium
14 Dropped out while receiving doubleglucocorticoid
15 Dropped out while receiving salmeterol

36 Dropped out during TALC treatment
phase
23 Withdrew consent
7 Were lost to follow-up
2 Had drug-related adverse event
1 Was found to be ineligible at visit 3
3 Had other reason

174 Completed TALC by May 2010

Figure 1. Enrollment and Outcomes.
The TALC and BASALT studies were companion trials that used a common run-in period: patients with better-controlled asthma were assigned to the BASALT trial, and those with poorer control were assigned to the TALC trial.
Shown are the numbers of patients who enrolled in the common run-in period, those who underwent randomization to each study, and those who completed the TALC study. At the start of the recruitment period, TALC study
drugs were not yet available, which accounted for the 57 patients who were assigned before the TALC start date, and
randomization of patients to the TALC trial ended before all patients were assigned to the BASALT trial, which accounted for the 22 patients who were assigned after TALC recruitment closed.

(i.e., a doubling of the run-in dose) plus a tiotropium placebo inhaler and salmeterol placebo inhaler; or the run-in dose of beclomethasone plus
salmeterol xinafoate (Serevent Diskus) at a dose
n engl j med 363;18

of 50 μg twice daily plus a tiotropium placebo
inhaler. Between each treatment, there was a
2-week washout period during which patients received only the run-in dose of beclomethasone to
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Figure 2. Outline of Study Protocol.
Shown are the durations of the common run-in, treatment, and washout periods, along with periods in which baseline data for variables that were collected daily were obtained before each treatment period. During the 4-week runin period and the 2-week washout periods, all patients received beclomethasone at a dose of 80 μg (2 puffs of 40 μg)
twice daily. Only three of the six possible treatment sequences are presented graphically.

establish baseline data for the next period. The cant differences are presented in Table 1 and in
study was conducted in accordance with the pro- the Supplementary Appendix.) Additional prespecitocol, which is available at NEJM.org.
fied exploratory hypotheses are listed in the Supplementary Appendix.15 Also prespecified was an
Outcome Measures
analysis of patients’ responses to the various study
The predetermined primary outcome measure was drugs, singly and in combination (a responder
the morning PEF. Predetermined secondary out- analysis).16,17
come measures included the FEV1 before bronchodilation, the number of asthma-control days Study Oversight
(defined as days without symptoms and without The study was funded by the National Heart, Lung,
the use of a rescue bronchodilator), asthma symp- and Blood Institute. The protocol was approved
toms, rescue-bronchodilator use, asthma exacer- by the protocol review committee of the institute’s
bations (defined as increased asthma symptoms Asthma Clinical Research Network and monitored
resulting in the use of oral glucocorticoids or the by the network’s data and safety monitoring
increased use of inhaled glucocorticoids or other board. Tiotropium was used under the provisions
asthma medications), use of health care services, of an approved application for an investigational
biomarkers of airway inflammation, and results new drug, submitted by the network’s data coorof validated questionnaires, including the Asthma dinating center. Beclomethasone canisters conControl Questionnaire,11,12 the Asthma Symptom taining either 40 μg or 80 μg and rescue albuterol
Utility Index,13 and the Asthma Quality-of-Life (Pro-Air) were supplied by Teva Specialty PharQuestionnaire.14 (For all questionnaires, the rang- maceuticals. Tiotropium and matching placebo
es, interpretations, and minimal clinically signifi- were supplied by Boehringer Ingelheim Pharma1718
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Table 1. Baseline Characteristics of the 210 Patients.*
Characteristic

Value

Male sex — no. (%)

69 (32.9)

One or more positive skin tests for atopy — no./total no. (%)

175/200 (87.5)

Age at visit 1 — yr

42.2±12.3

Duration of asthma — yr

26.1±14.1

Weight at visit 1 — kg

88.3±25.3

Body-mass index at visit 1†

31.4±8.8

FEV1
Value at visit 3 before bronchodilation — liters

2.31±0.77

Percent of predicted value at visit 3 before bronchodilation

71.5±14.9

Percent reversal of obstruction with albuterol (4 puffs) at visit 3

14.9±9.8

Value after albuterol (4 puffs) at visit 3 — liters

2.64±0.82

Percent reversal of obstruction with ipratropium (4 puffs) at visit 2

12.4±9.5

Value after ipratropium (4 puffs) at visit 2 — liters

2.62±0.80

PEF before visit 3 (2-wk mean) — liters/min
Morning

377.2±117.0

Evening

383.6±119.0

Daily-symptom score before visit 3 (2-wk mean)‡

0.46±0.44

Albuterol rescue use before visit 3 (2-wk mean) — puffs/day

1.71±2.09

Asthma-control days before visit 3 (2-week mean)
Proportion of days

0.212±0.331

No. of days

2.97±4.64

Asthma Control Questionnaire score at visit 3§

1.64±0.73

Asthma Quality-of-Life Questionnaire score at visit 3¶

5.43±1.05

Asthma Symptom Utility Index score at visit 3‖

0.78±0.15

Geometric mean exhaled nitric oxide at visit 3 — ppb (coefficient of variation)

18.8 (0.7)

* Plus–minus values are means ±SD. FEV1 denotes forced expiratory volume in 1 second, and PEF peak expiratory flow.
† The body-mass index is the weight in kilograms divided by the square of the height in meters.
‡ Daily symptoms were evaluated on a scale from 0 to 3, with a higher score indicating a greater severity of symptoms.
§ Scores on the Asthma Control Questionnaire range from 0 to 6, with a higher score indicating worse asthma control;
the minimal clinically important difference (MID) is 0.5.
¶ Scores on the Asthma Quality-of-Life Questionnaire range from 1 to 7, with a higher score indicating a better quality
of life; the MID is 0.5.
‖ Scores on the Asthma Symptom Utility Index range from 0 to 1, with a higher score indicating better asthma control;
the MID is unknown, but a difference of 0.3 is suggested to distinguish between mild-to-moderate and moderate-tosevere asthma.

ceuticals, which had the opportunity to comment
on the study design. This input resulted in an increase in the sample size to include more patients
with the Arg/Arg polymorphism in the gene encoding the β2-adrenergic receptor. The company
had no role in the performance of the trial, the
analysis or interpretation of the data, the preparation of the manuscript, or the decision to submit
the manuscript for publication. Salmeterol and
matching placebo were purchased from third-party
n engl j med 363;18

vendors. Medication use was measured by means
of an electronic device (for beclomethasone), a
counter for dry-powder inhalers (for salmeterol),
and assessment of used blister packs (for tiotropium), with mean (±SD) rates of compliance of
84.1±16.2%, 92.6±12.3%, and 93.0±12.2%, respectively.
The informed-consent document was amended in April 2008 to acknowledge the FDA’s MedWatch alert regarding the association between
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Table 2. Outcome Variables.*
Variable

Mean Change from Baseline
Tiotropium

P Value

P Value

Salmeterol

P Value

Morning PEF — liters/min

24.4 (16.0 to 32.7)

<0.001

−1.4 (−8.4 to 5.6)

0.69

18.0 (11.5 to 24.5)

<0.001

Evening PEF — liters/min

29.6 (21.9 to 37.3)

<0.001

−5.7 (−12.3 to 0.9)

0.09

19.0 (11.7 to 26.3)

<0.001

−0.11 (−0.26 to 0.03)

0.12

−0.07 (−0.19 to 0.06)

0.30

−0.16 (−0.28 to −0.03)

0.01

Albuterol rescue use
— puffs/day

Double-Glucocorticoid

Mean daily-symptom score −0.09 (−0.12 to −0.05)

<0.001

0.03 (−0.01 to 0.06)

0.11

−0.04 (−0.08 to −0.01)

0.02

Proportion of asthmacontrol days

0.131 (0.090 to 0.171)

<0.001

0.051 (0.010 to 0.093)

0.02

0.139 (0.096 to 0.183)

<0.001

Prebronchodilator FEV1
— liters

0.12 (0.07 to 0.17)

<0.001

0.02 (−0.03 to 0.07)

0.47

0.01 (−0.04 to 0.06)

0.60

Asthma Symptom Utility
Index score

0.03 (0.01 to 0.05)

0.004

0.00 (−0.02 to 0.02)

0.77

0.04 (0.03 to 0.06)

<0.001

Asthma Control
Questionnaire score

−0.22 (−0.33 to −0.11)

<0.001

−0.03 (−0.13 to 0.06)

0.49

−0.31 (−0.40 to −0.22)

<0.001

Asthma Quality-of-Life
Questionnaire score

0.15 (0.03 to 0.26)

0.01

0.05 (−0.06 to 0.15)

0.38

0.28 (0.18 to 0.38)

<0.001

FEV1 after 4 puffs of
albuterol — liters

0.02 (−0.01 to 0.05)

0.16

−0.02 (−0.05 to 0.01)

0.11

−0.05 (−0.08 to −0.03)

<0.001

* Values in parentheses are 95% confidence intervals. Restricted maximum-likelihood estimates were determined for the treatment effects
(the model-based change between the beginning and the end of each of the three treatment periods). Patients received tiotropium or sal
meterol in addition to a low dose of beclomethasone or received a double dose of beclomethasone. The primary comparison was between
tiotropium and double-glucocorticoid. The secondary comparison was between tiotropium and salmeterol. The comparison between salmeterol and double-glucocorticoid was performed to determine whether the patients in the TALC study were similar to those in previous trials
comparing long-acting beta-agonists with inhaled glucocorticoids. FEV1 denotes forced expiratory volume in 1 second, and PEF peak expiratory flow.

tiotropium and the risk of stroke. No patient with- pium to an inhaled glucocorticoid and the doudrew because of this modification.
bling of the dose of an inhaled glucocorticoid,
an active control. The study also had a power of
Statistical Analysis
90% to detect a between-treatment difference in
The primary hypothesis was that the addition of the proportion of asthma-control days of 0.07
tiotropium to an inhaled glucocorticoid would be and a power of 93% to detect a between-treatment
superior to a doubling of the dose of the inhaled difference in the prebronchodilator FEV1 of 0.09
glucocorticoid with respect to the morning PEF. liters.
The secondary hypothesis was that the addition
Descriptive statistics were counts and percentof tiotropium to an inhaled glucocorticoid would ages for categorical variables, means and standard
not be inferior to the addition of salmeterol with deviations for normally distributed variables, georespect to the morning PEF, the prebronchodilator metric means and coefficients of variation for
FEV1, and the proportion of asthma-control days. normally distributed log-transformed variables,
All analyses were performed according to the in- and medians and first and third quartiles for
tention-to-treat principle.
variables that were not normally distributed on
The original target sample size of 224 patients the original or log-transformed scales.
was reduced in May 2009 to 210 patients, which
A linear mixed-effects model was applied to
provided a power of 90% for detecting a between- crossover data for each continuous outcome varitreatment difference of 10.6 liters per minute in able.18-20 Fixed-effects terms included clinical
the morning PEF on the basis of a one-sided sig- center (stratifying variable), treatment regimen,
nificance level of 0.025, allowing for a dropout treatment sequence, treatment period, and horate of 10%. This effect size was chosen because mogeneous carryover effects. Evaluation of clinof the comparison between the addition of tiotro- ical outcomes was performed at weeks 0, 4, 9, and
1720
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Mean Difference in Change from Baseline
Tiotropium vs. DoubleGlucocorticoid

P Value

Tiotropium vs.
Salmeterol

P Value

Salmeterol vs. DoubleGlucocorticoid

25.8 (14.4 to 37.1)

<0.001

6.4 (−4.8 to 17.5)

0.26

19.4 (9.4 to 29.4)

<0.001

35.3 (24.6 to 46.0)

<0.001

10.6 (−0.1 to 21.3)

0.05

24.7 (15.2 to 34.3)

<0.001

−0.05 (−0.24 to 0.14)

0.63

0.04 (−0.13 to 0.22)

0.63

−0.09 (−0.27 to 0.09)

0.33

P Value

−0.11 (−0.16 to −0.06)

<0.001

−0.04 (−0.09 to 0.01)

0.10

−0.07 (−0.12 to −0.02)

0.005

0.079 (0.019 to 0.140)

0.01

−0.009 (−0.070 to 0.053)

0.78

0.088 (0.028 to 0.148)

0.004

0.10 (0.03 to 0.17)

0.004

0.11 (0.04 to 0.18)

0.003

0.00 (−0.08 to 0.07)

0.89

0.03 (0.00 to 0.06)

0.09

−0.01 (−0.04 to 0.02)

0.38

0.04 (0.01 to 0.07)

0.005

−0.18 (−0.34 to −0.03)

0.02

0.09 (−0.04 to 0.23)

0.18

−0.28 (−0.41 to −0.15)

<0.001

0.10 (−0.07 to 0.27)

0.24

−0.13 (−0.28 to 0.02)

0.09

0.23 (0.09 to 0.37)

0.002

0.04 (0.01 to 0.08)

0.01

0.07 (0.05 to 0.10)

<0.001

−0.03 (−0.06 to 0.00)

0.06

14 during each 14-week treatment period. Outcomes that were recorded on daily diary cards
were averaged between visits, so that the week 0
measurement represented the mean during the
last 2 weeks of the run-in period or the 2 weeks
of the washout period between treatments, the
week 4 measurement represented the mean between week 0 and week 4, and so forth. Restricted maximum-likelihood estimates were determined for the treatment effects (the model-based
change between week 0 and week 14) with the
use of PROC MIXED of the SAS/STAT statisticalanalysis software, version 9.2 (SAS Institute). The
null hypothesis of inferiority for the secondary
hypothesis was rejected in favor of noninferiority if the upper 97.5% confidence limit for the difference between salmeterol treatment and tiotropium treatment was less than the prespecified
bound (10.6 liters per minute for the morning PEF,
0.07 for the proportion of asthma-control days,
and 0.09 liters for the prebronchodilator FEV1).
The statistical analysis plans included an exploratory analysis to identify patients, among
those who completed the trial, with certain prespecified responses with respect to the morning
PEF, prebronchodilator FEV1, and asthma-control
days.16,17 We defined a lung-function response
as a relative increase in the morning PEF or FEV1
of at least 7.5% and an asthma-control-day ren engl j med 363;18

sponse as a proportional increase of at least 0.10.
Data regarding the morning PEF and asthmacontrol days were collected daily; therefore, 2-week
averages before baseline and at the end of the
treatment period were used to characterize the
response. In addition, using information from
Lemanske and colleagues,21 we defined a threedimensional response as a positive response with
respect to both lung function (either morning PEF
or FEV1) and the number of asthma-control days,
with no exacerbations of asthma. We defined a
two-dimensional response as a positive response
with respect to either lung function or the number of asthma-control days, with no asthma exacerbations. These definitions were not prespecified but were established before the data were
examined.

R e sult s
Study Patients

Of the 210 study patients, 141 (67.1%) were women;
59 (28.1%) were black, and 24 (11.4%) were Hispanic (Table 1, and Table S1 in the Supplementary
Appendix). The mean baseline FEV1 before bronchodilation was 2.31±0.77 liters (71.5±14.9% of
the predicted value), and the mean score on the
Asthma Control Questionnaire was 1.64±0.73. The
mean percentages of reversibility of airway ob-
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struction after four puffs of albuterol and ipratropium bromide were 14.9±9.8% and 12.4±9.5%, respectively. The mean morning PEF was 377.2±117.0
liters per minute, and the proportion of asthmacontrol days was 0.21±0.33 (2.97±4.64 days) during the 2 weeks before randomization. Baseline
values before each of the three active treatment
periods were similar for the morning PEF (377.2±
117.0, 383.9±117.6, and 383.0±115.0 liters per minute, respectively) and FEV1 (2.31±0.77, 2.36±0.77,
and 2.36±0.75 liters, respectively), whereas the proportion of asthma-control days increased from
0.21±0.33 before treatment period 1 to 0.34±0.40
and 0.34±0.41 before treatment periods 2 and 3,
respectively. Although minimal carryover effects
between periods were observed for measures of
lung function, an effect was seen for asthmacontrol days (Table S2 in the Supplementary Appendix). Markers of inflammation at randomization (exhaled nitric oxide and sputum eosinophils)
were low at baseline and thereafter.
Primary Outcome

Patients receiving tiotropium had a morning PEF
that was 25.8 liters per minute higher than that
of patients receiving a double dose of glucocorticoid (95% confidence interval [CI], 14.4 to 37.1;
P<0.001) (Table 2, and Table S3 in the Supplementary Appendix). Similar results favoring tiotropium over a double glucocorticoid dose were obtained for the evening PEF, with a difference of
35.3 liters per minute (95% CI, 24.6 to 46.0;
P<0.001); the prebronchodilator FEV1, with a difference of 0.10 liters (95% CI, 0.03 to 0.17;
P = 0.004); the proportion of asthma-control days,
with a difference of 0.079 (95% CI, 0.019 to 0.140;
P = 0.01); score for daily symptoms, with a difference of −0.11 points (95% CI, −0.16 to −0.06;
P<0.001); the score on the Asthma Control Questionnaire, with a difference of −0.18 points (95%
CI, −0.34 to −0.03; P = 0.02); and the FEV1 after
four puffs of albuterol, with a difference of 0.04
liters (95% CI, 0.01 to 0.08; P = 0.01).
Secondary Outcomes

There were no significant differences between
tiotropium treatment and salmeterol treatment
with respect to the morning PEF, which was
6.4 liters per minute higher among patients receiving tiotropium (95% CI, −4.8 to 17.5; P = 0.26); the
evening PEF, with a difference of 10.6 liters per
minute (95% CI, −0.1 to 21.3; P = 0.05); the proportion of asthma control days, with a difference of
1722
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−0.009 (95% CI, −0.070 to 0.053; P = 0.78); the
score for daily symptoms, with a difference of
−0.04 points (95% CI, −0.09 to 0.01; P = 0.10); the
score on the Asthma Control Questionnaire, with
a difference of 0.09 (95% CI, −0.04 to 0.23; P = 0.18);
and a difference in the proportion of sputum eosinophils of 0.20% (95% CI, −0.36 to 0.76; P = 0.49)
(Table S3 in the Supplementary Appendix). The
null hypothesis of inferiority was rejected in favor
of the alternative hypothesis of noninferiority at
the 0.025 significance level for the morning PEF,
the prebronchodilator FEV1, and the proportion of
asthma-control days. The prebronchodilator FEV1
favored tiotropium, with an increase of 0.11 liters
(95% CI, 0.04 to 0.18; P = 0.003), as did the FEV1
after four puffs of albuterol, with an increase of
0.07 liters (95% CI, 0.05 to 0.10; P<0.001).
Comparison of Salmeterol and Double-Dose
Glucocorticoid

This comparison was performed to determine
whether the patients in the TALC study were similar to those in previous trials comparing LABA
with an inhaled glucocorticoid.3,4 Salmeterol was
superior to the double dose of beclomethasone
with respect to the morning PEF, with a betweengroup difference of 19.4 liters per minute (95%
CI, 9.4 to 29.4; P<0.001); the evening PEF, with a
difference of 24.7 liters per minute (95% CI, 15.2
to 34.3; P<0.001); the proportion of asthma-control days, with a difference of 0.088 (95% CI, 0.028
to 0.148; P = 0.004); the daily-symptom score,
with a difference of −0.07 units (95% CI, −0.12 to
−0.02; P = 0.005); the score on the Asthma Control
Questionnaire, with a difference of −0.28 (95% CI,
−0.41 to −0.15; P<0.001); the score on the Asthma Symptom Utility Index, with a difference of
0.04 units (95% CI, 0.01 to 0.07; P = 0.005); and
the score on the Asthma Quality-of-Life Questionnaire, with a difference of 0.23 units (95% CI,
0.09 to 0.37; P = 0.002). A summary of changes in
the morning and evening PEF, the prebronchodilator FEV1, and the proportion of asthma-control
days (per 2-week period) according to treatment
period is shown in Figure 3.
Exploratory Response Analyses

The proportions of patients with a two-dimensional response or a three-dimensional response to the
various treatments are shown in Table 3. A total
of 31.3% of patients had a two-dimensional response to all three treatment regimens, whereas
9.4% had no such response to any of them. A small
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Figure 3. Primary and Secondary Outcomes.
Shown are the mean differences among patients receiving tiotropium, those receiving double-glucocorticoid, and those receiving sal
meterol with respect to the morning peak expiratory flow (PEF) (Panel A), the evening PEF (Panel B), the prebronchodilator forced expiratory volume in 1 second (FEV1) (Panel C), and the proportion of asthma-control days per 14-day period (Panel D). The I bars indicate
95% confidence intervals.

proportion of patients (5.6 to 8.8%) had a response
to only one treatment. Two-dimensional responses occurred in 66.3% of patients receiving tiotropium, 53.1% of those receiving double-glucocorticoid, and 70.6% of those receiving salmeterol.
Asthma Exacerbations and Adverse Events

An asthma exacerbation occurred in 9 patients
receiving tiotropium, 16 receiving double-glucocorticoid, and 5 receiving salmeterol; the respective numbers of patients with asthma exacerbations for which oral or intravenous glucocorticoids
were administered were 7, 13, and 5. Patients receiving the double dose of beclomethasone had
the highest numbers of unscheduled visits for
asthma symptoms (2 for tiotropium, 6 for double-glucocorticoid, and 2 for salmeterol), emergency room visits (2, 4, and 1, respectively), and
n engl j med 363;18

events for which urgent care was needed (4, 9,
and 3, respectively). Two hospitalizations for asthma occurred, 1 among patients receiving tiotropium and 1 among those receiving double-glucocorticoid. Reasons for withdrawal from the trial
(7 for tiotropium, 14 for double-glucocorticoid,
and 15 for salmeterol) are provided in Table S4 in
the Supplementary Appendix.
A total of 12 serious adverse events involving
hospitalization or an emergency room visit occurred: 3 among patients receiving tiotropium
(2 hospitalizations for pneumonia and 1 for a
fractured radius), 4 among those receiving double-glucocorticoid (1 hospitalization for spinal
stenosis surgery, 1 for atypical chest pain, 1 for
transient global amnesia, and 1 for pneumonia),
4 among those receiving salmeterol (1 hospitalization and subsequent death from sepsis after
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* Patients received tiotropium or salmeterol in addition to a low dose of beclomethasone or received a double dose of beclomethasone. FEV1 denotes forced expiratory volume in 1 second,
and PEF peak expiratory flow.
† An asthma-control-day response was defined as a proportional increase of at least 0.10.
‡ A two-dimensional response was defined as a positive response in lung function or in the number of asthma-control days, with no asthma exacerbations.
§ A three-dimensional response was defined as a positive response in both lung function (either morning PEF or FEV1) and the number of asthma-control days, with no asthma exacerbations.

160 (100.0)
1 (0.6)
21 (13.1)
93 (58.1)
Three-dimensional response§

9 (5.6)

19 (11.9)

3 (1.9)

13 (8.1)

1 (0.6)

166 (100.0)

160 (100.0)

29 (17.5)

50 (31.3)
17 (10.6)

9 (5.4)
19 (11.4)

33 (20.6)
9 (5.6)

12 (7.2)
17 (10.2)

13 (8.1)

9 (5.4)

15 (9.4)

14 (8.8)

63 (38.0)
Asthma-control days†

Two-dimensional response‡

8 (4.8)

168 (100.0)
2 (1.2)
32 (19.0)
4 (2.4)
28 (16.7)
10 (6.0)
30 (17.9)
57 (33.9)
Morning PEF

9 (5.6)

166 (100.0)
1 (0.6)
6 (3.6)
14 (8.4)

number of patients (percent)

11 (6.6)
17 (10.2)
12 (7.2)
73 (44.0)
FEV1

32 (19.3)

5 (3.0)

All Patients
No Response
Variable

Table 3. Response to Treatment.*
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Only

DoubleGlucocorticoid
Only

Salmeterol
Only

Tiotropium
plus DoubleGlucocorticoid

Tiotropium
plus Salmeterol

Salmeterol
plus DoubleGlucocorticoid

Tiotropium
plus Salmeterol
plus DoubleGlucocorticoid
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hysterectomy for endometrial carcinoma, 1 hospitalization for hysterectomy to remove fibroids,
1 hospitalization for knee-replacement surgery,
and 1 emergency room visit for stridor after ingestion of orange juice), and 1 during the singledose-glucocorticoid run-out period (hospitalization for tonsillitis).

Discussion
We report two findings with implications for the
treatment of asthma in adults. First, our study
shows that the use of tiotropium was superior to
a doubling of the dose of an inhaled glucocorticoid for patients whose symptoms were inadequately controlled while they were receiving inhaled beclomethasone alone at a dose of 80 μg
twice a day. Second, among patients in our study
who were similar to those in trials showing the
clinical efficacy of LABA therapy,3,4 tiotropium was
noninferior to salmeterol on the basis of predefined
criteria, a finding that meets the standards established in the FDA’s draft guidance for industry on noninferiority clinical trials.22
Our selection of the morning PEF as the primary outcome might attract criticism, even though
the trial was adequately powered and analyzed
for another key patient-centric outcome, the proportion of asthma-control days. Our rationale was
that pulmonary function remains an important
element of asthma control, improvements in the
PEF were similar to those in previous Asthma
Clinical Research Network trials comparing an
active treatment with placebo,23,24 and improvements in pulmonary function that were induced
by tiotropium were accompanied by improvements
in both asthma symptoms and the proportion of
asthma-control days.
We did not evaluate whether increasing the
dose of an inhaled glucocorticoid by more than
a factor of two would provide an increased bene
fit. Although an increase in the dose of an inhaled glucocorticoid by a factor of four has been
reported to reduce asthma exacerbations,25 low
doses of an inhaled glucocorticoid have been reported to provide a benefit equivalent to that of
a high dose with respect to measures of asthma
control,26 the outcomes that we studied. In addition, combinations of inhaled glucocorticoids and
LABA therapy have been reported to provide superior asthma control, as compared with an increased dose of an inhaled glucocorticoid, even
when the dose was more than doubled.27
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Although the effects of tiotropium and salmet
erol were similar in general, measures of the
prebronchodilator FEV1 favored tiotropium. The
small decrease in FEV1 after four puffs of albuterol
among patients receiving salmeterol (0.05 liters)
suggests possible tachyphylaxis to the effect of
an additional dose of a beta-agonist, a finding
not observed in the tiotropium group (with an
increase of 0.02 liters). At baseline, the shortterm response to four puffs of albuterol (reversibility of airway obstruction of 14.9%) was similar to the response to four puffs of ipratropium
(reversibility of 12.4%), which suggests that ipratropium could be considered as an acute bronchodilator for patients with asthma, as was
shown in the Asthma Clinical Research Network’s Long-Acting Beta Agonist Response by
Genotype (LARGE) trial (NCT00200967).28
The exploratory response analysis provides
several insights. In evaluating the response to
treatment on the basis of the very stringent threedimensional measurement, we found that only
36% of patients receiving a bronchodilator and an
inhaled glucocorticoid had such a response, as
compared with less than 10% of patients receiving
a double dose of an inhaled glucocorticoid (Table 3). These data could be used to examine how
treatment responses are distributed in a population of patients with asthma. For example, if the
less stringent two-dimensional criteria were applied and if the goal were to treat the greatest
number of patients with a drug to which they had
a response and to maximize the use of inhaled
glucocorticoids, 53.1% of patients would be treat-

ed with a double dose of an inhaled glucocorticoid, 8.8% with tiotropium plus an inhaled glucocorticoid, and 8.1% with salmeterol plus an
inhaled glucocorticoid, leaving 20.6% to be treated with either one of the bronchodilators combined with a low-dose inhaled glucocorticoid and
9.4% who had no response to any treatment.
On the basis of our study’s design, we evaluated only a small number of patients, with no
treatment lasting longer than 14 weeks. Since we
could not examine either the rate of asthma exacerbations or long-term safety issues, our findings cannot be considered clinically directive.
Additional studies that have sufficient statistical
power to evaluate exacerbations and safety events
are required to further establish the clinical efficacy of tiotropium. However, our data establish
clinical equipoise to study larger cohorts of adults
for longer periods of time with tiotropium as a
therapy for asthma control.
Supported by grants from the National Heart, Lung, and
Blood Institute (U10 HL074225, U10 HL074227, U10 HL074231,
U10 HL074204, U10 HL074212, U10 HL074073, U10 HL074206,
U10 HL074208, and U10 HL074218).
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
We thank all the patients who took part in this trial; the members of the data and safety monitoring board, Andrea Apter, Serpil
Erzurum, Barbara Layman, Yancy Phillips, Bruce Psaty, and James
Sheller; and our study coordinators, Denise Beaver, Kelly Bixler,
Jennifer Brandorff, Terry Britton, Peggy Cadbury, Alyson Clayborn, Vanessa Curtis, Mary Gill, Robert Hmieleski, Donna Jinwright, Christena Kolakowski, Jeffrey Krings, Lauren Leshak,
Aimee Merchlinski, Barbara Miller, Surinder Narula, Brenda Patterson, Melanie Payton, Jean Schenkkan, Ann Sexton, Kerrie
Sheaffer, Allen Stevens, Melissa Thrasher, Suzanne Vogt, Rhonda
Webb, Lynda Weichel-Williams, Cheryl Wilmoth, Tiffany Wirth,
Muhammad Zahid, Ronald Zimmerman, and Kathy Zheng.

References
1. Global Initiative for Asthma (GINA)

home page. (http://www.ginasthma.com.)
2. National Asthma Education and Prevention Program. Expert panel report III:
guidelines for the diagnosis and management of asthma. Bethesda, MD: National
Heart, Lung, and Blood Institute, 2007.
(NIH publication no. 08-4051.) (http://
www.nhlbi.nih.gov/guidelines/asthma/
asthgdln.htm.)
3. Woolcock A, Lundback B, Ringdal N,
Jacques LA. Comparison of addition of
salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am
J Respir Crit Care Med 1996;153:1481-8.
4. Gibson PG, Powell H, Ducharme FM.
Differential effects of maintenance longacting beta-agonist and inhaled corticosteroid on asthma control and asthma
exacerbations. J Allergy Clin Immunol
2007;119:344-50.

5. Long-acting beta agonist (LABA) infor-

mation. Rockville, MD: Food and Drug Administration. (http://www.fda.gov/Drugs/
DrugSafety/InformationbyDrugClass/
ucm199565.htm.)
6. Drazen JM, O’Byrne PM. Risks of longacting beta-agonists in achieving asthma
control. N Engl J Med 2009;360:1671-2.
7. von Mutius E, Drazen JM. Choosing
asthma step-up care. N Engl J Med 2010;
362:1042-3.
8. Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in
adults. Cochrane Database Syst Rev 2004;3:
CD003269.
9. Barnes PJ. The pharmacological properties of tiotropium. Chest 2000;117:
Suppl:63S-66S.
10. Idem. Tiotropium bromide. Expert
Opin Investig Drugs 2001;10:733-40.
11. Juniper EF, O’Byrne PM, Guyatt GH,

n engl j med 363;18

nejm.org

Ferrie PJ, King DR. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999;14:902-7.
12. Juniper EF, Svensson K, Mörk AC,
Ståhl E. Measurement properties and interpretation of three shortened versions
of the Asthma Control Questionnaire.
Respir Med 2005;99:553-8.
13. Revicki DA, Leidy NK, Brennan-Diemer
F, Sorensen S, Togias A. Integrating patient
preferences into health outcomes assessment. Chest 1998;114:998-1007.
14. Juniper EF, Guyatt GH, Cox FM, Ferrie
PJ, King DR. Development and validation
of the Mini Asthma Quality of Life Questionnaire. Eur Respir J 1999;14:32-8.
15. Bateman ED, Boushey HA, Bousquet
J, et al. Can guideline-defined asthma
control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir
Crit Care Med 2004;170:836-44.

october 28, 2010

1725

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on September 10, 2014. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.

Tiotropium Step-Up Ther apy for Uncontrolled Asthma
16. Szefler SJ, Phillips BR, Martinez FD,

et al. Characterization of within-subject
responses to fluticasone and montelukast
in childhood asthma. J Allergy Clin Immunol 2005;115:233-42.
17. Zeiger RS, Szefler SJ, Phillips BR, et
al. Response profiles to fluticasone and
montelukast in mild-to-moderate persistent childhood asthma. J Allergy Clin Immunol 2006;117:45-52.
18. Laird NM, Ware JH. Random effects
models for longitudinal data. Biometrics
1982;38:963-74.
19. Jennrich RI, Schluchter MD. Unbalanced repeated measures models with
structured covariance matrices. Biometrics 1986;42:805-20.
20. Vonesh EF, Chinchilli VM. Linear and
nonlinear models for the analysis of repeated measurements. New York: Marcel
Dekker, 1997.
21. Lemanske RF Jr, Mauger DT, Sorkness
CA, et al. Step-up therapy for children with

uncontrolled asthma receiving inhaled
corticosteroids. N Engl J Med 2010;362:97585.
22. Guidance for industry: non-inferiority
clinical trials: draft guidance. Rockville,
MD: Food and Drug Administration, 2010.
(http://www.fda.gov/downloads/Drugs/
GuidanceComplianceRegulatory
Information/Guidances/UCM202140.pdf.)
23. Lazarus SC, Boushey HA, Fahy JV, et
al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent
asthma: a randomized controlled trial.
JAMA 2001;285:2583-93.
24. Lemanske RF Jr, Sorkness CA, Mauger
EA, et al. Inhaled corticosteroid reduction
and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001;
285:2594-603.
25. Pauwels RA, Löfdahl CG, Postma DS,
et al. Effect of inhaled formoterol and

budesonide on exacerbations of asthma.
N Engl J Med 1997;337:1405-11. [Erratum,
N Engl J Med 1998;338:139.]
26. Powell H, Gibson PG. High dose versus low dose inhaled corticosteroid as
initial starting dose for asthma in adults
and children. Cochrane Database Syst Rev
2004;2:CD004109.
27. Greenstone IR, Ni Chroinin MN,
Masse V, et al. Combination of inhaled
long-acting beta2-agonists and inhaled
steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev
2005;4:CD005533.
28. Wechsler ME, Kunselman SJ, Chinchilli VM, et al. Effect of beta2-adrenergic
receptor polymorphism on response to
longacting beta2 agonist in asthma
(LARGE trial): a genotype-stratified, randomised, placebo-controlled, crossover
trial. Lancet 2009;374:1754-64.
Copyright © 2010 Massachusetts Medical Society.

personal archives in the journal online

Individual subscribers can store articles and searches using a feature
on the Journal’s Web site (NEJM.org) called “Personal Archive.”
Each article and search result links to this feature. Users can create
personal folders and move articles into them for convenient retrieval later.

1726

n engl j med 363;18

nejm.org

october 28, 2010

The New England Journal of Medicine
Downloaded from nejm.org at WASHINGTON UNIV SCH MED MEDICAL LIB on September 10, 2014. For personal use only. No other uses without permission.
Copyright © 2010 Massachusetts Medical Society. All rights reserved.

